UCB extends label for anti-epilepsy drug to include children

Belgium’s UCB has successfully expanded the marketable use for its anti-epileptic drug Vimpat (lacosamide) in Europe.

The EMA has approved Vimpat as monotherapy and adjunctive therapy for certain adult and pediatric patients, in the treatment of partial-onset seizures.

The decision is based on extrapolated efficacy data from a trial in adults, and is supported by safety and pharmacokinetics data collected in children.

The drug is approved in 72 countries. In the USA, it is not approved in pediatric populations.